alexa Extended Release Orally Disintegrating Dosage Forms are Potential Techniques to Deliver and Maintain the Therapeutic Ranges of Plasma Drug Concentrations | Open Access Journals
ISSN: 1920-4159
Journal of Applied Pharmacy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Extended Release Orally Disintegrating Dosage Forms are Potential Techniques to Deliver and Maintain the Therapeutic Ranges of Plasma Drug Concentrations

Taha Nazir*

Intellectual Consortium of Drug Discovery & Technology Development Incorporation, Saskatoon SK S7L3E4 Canada

*Corresponding Author:
Taha Nazir
Intellectual Consortium of Drug Discovery & Technology
Development Incorporation, Saskatoon SK S7L3E4 Canada
Tel: +92 321 222 0885
E-mail: [email protected]; [email protected]

Received date: October 02, 2014 Accepted date: October 06, 2015 Published date: October 15, 2015

Citation: Nazir T (2015) Extended Release Orally Disintegrating Dosage Forms are Potential Techniques to Deliver and Maintain the Therapeutic Ranges of Plasma Drug Concentrations. J App Pharm 7:e101. doi: 10.4172/1920-4159.1000e101

Copyright: © 2015 Taha Nazir. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Applied Pharmacy

Keywords

Drug delivery; Therapeutic concentrations; Orally disintegrating dosage forms; Extended release drugs

Currently, in modern technology, new and innovative techniques are emerging up in the field of Drug Delivery System. Extended release orally disintegrating technology help’s to maintain a therapeutic range of plasma drug concentrations for a longer time [1,9]. Therefore, we aimed to present such new and modern drug delivery system with dual character of orodispersible as well as extended release profile in order to enhance patient compliance. However, as the demand for Mouth Disintegrating Tablets (MDT’s) continues to grow, therefore scientists are exploring ways to adapt MDT formulations for drugs that require extended release profile for optimal therapeutic benefits [2,3].

In addition of that, there are certain other techniques to manufacture the MDT’s, the Center of Drug Evaluation and Research (CDER) Nomenclature Standards Committee has defined an Orally Disintegrating Tablet (ODT) as “Solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue” in 1998 [5]. Some of the new advanced technologies which are commonly being used in last few decades are Freeze drying/ Lyophilization, Molding, Direct Compression, Cotton Candy Process, Spray Drying, Sublimation and Mass Extrusion [4].

Moreover, the controlled or extended release orally disintegrating technologies offer potential drug delivery systems to provide optimum regimens of therapeutic value [6,7]. Such dosage forms enhance the efficacy, reduce toxicity and assure patient’s drug compliance. Whereas, the extended release orally disintegrating technology reduces frequency, shorten the half-lives and help to avoid the undesired troughs and peaks of plasma drug concentrations to obtain the time variant efficacy associated with rapid drug release. Moreover, once a day extended release formulations offer an additional advantage for the special population where compliance is matter [10].

Orally disintegrating preparations are quickly dissolved in oral cavity and more convenient to administer to the patients of special populations. In addition of that, such dosage forms also provide additional advantages for patients experiencing dysphagia, brain or spinal cord injury, neurological disorders, multiple sclerosis, stroke, Parkinson’s disease or muscular dystrophy. Thus, extended release orally disintegrating technologies provide benefit to the patient of gastro oesophageal reflux disease, esophagitis as well as oesophageal cancer. Whereas, the rapidly disintegrating dosage forms are dissolved in the mouth to add clinical effect of therapeutical value. Therefore, the pharmaceutical institutions are working to mask the taste and enhance the palatability to develop orally disintegrating extended release dosage forms. Thus, a variety of excipients with different polymer systems and solvents are trailed to encapsulate the active drugs, resulting fine particles with polymer coated dosage forms. These particles are then incorporated into extended release orally disintegrating technology matrix.[9] The resulting dosage forms are then provide a variety of custom release profiles ranging from immediate, delayed, extended release to once daily regimen.

There are certain pharmaceutical preparations i.e. OraSolv®, DuraSolv®, Lyoc successful designed with extended release profiles. These technologies qualify the standards defined by the Centre for Drug Evaluation and Research for a solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue [13].

In addition of that, the plasma drug concentrations remain within therapeutic window for a longer time as compared with conventional rapid release formulations [12]. These dosage forms are convenient in administration and disintegration in the mouth and can be taken whenever and wherever patients want because of quick and convenient unit dose blister packaging [11].

Thus, the combination of extended release technology with oral dispersible technology can results in dosage forms that offer additional therapeutical value for patients including better compliance, decrease in dosing frequency, maintenance of therapeutic drug concentration and administration of drug to the patients of special population. The determinants of MDT, ODT and MDERT’s are adjustable within acceptable range to enhance the efficiency. Additionally, the extended release profile may also be designed to formulate the dosage forms to render the dose, regimen, protocol and frequency of patient in clinical practice.

References

  1. Anupama K, Shelly K, Neena B (2009) Formulation and evaluation of Mouth Dissolving tablets of Oxacarbazepine. International Journal of Pharmacy and Pharmaceutical Sciences1: 12-23.
  2. Ashish P, Harsoliya MS, Pahang JK, Shruti SA (2011) Review- Formulation of mouth   dissolving tablet. International Journal of Pharmaceutical and Clinical Science 1:1-8.
  3. Baldi F,Malfertheiner P (2003)Lansoprazole Fast Disintegrating Tablet: A New Formulation For An Established Proton Pump Inhibitor. Digestion 67: 1-5.
  4. Bandari S, Mittapalli RK, Gannu R, Rao YM (2008)Orodispersible tablets: An overview. Asian J of pharm 2: 2-11.
  5. Bankars K, Chaudhari AV, MahaleNB, Chaudhari SR (2014) A Review On OrodispersibleTabletsprepared Using Spray Dried Sustained Release Microparticles. Journal Of Advanced Drug Delivery 1: 82-95.
  6. Bhaskar DK, More MR, Sockan GN, Kunchu K, Tamiz Mani T (2011) Formulation and Evaluation of orodispersible tablets of propranolol hydrochloride. International journal of pharmaceutical research & development 2: 46-52.
  7. Biswajit B, Joshi V (2011) Formulation And Evaluation Of Orodispersible Tablets Of Amlodipine Besilate. Int Journal Of Pharmacy And Technology 3: 3745-3766.
  8. Fu Y, Yang S, Jeong SH, Kimura S, Park K (2004). Orally Fast Disintegrating Tablets: Developments, Technologies Taste Masking and Clinical Studies. Crit Rev Ther Drug Carrier Syst 21:433-476.
  9. Gopi MVenkatesh, Phillip J Stevens, Jin-Wang Lai (2012) Development of Orally Disintegrating Tablets Comprising Controlled-Release Multiparticulate Beads. Drug Development and Industrial Pharmacy, 2012; 38(12): 1428-1440.
  10. HarshaKathpalia, BhairaviSule, AshwiniPatil, AnaghaMahadik, Komal Sharma (2014) Controlled Release Orally Disintegrating Tablets: A Review. Int J Pharm Sci Rev Res 24: 35-42.
  11. Marshall K, Lachman N, Liberman HA (1987) The Theory and Practice of Industrial Pharmacy. (3rdedn) Varghese Publishing House, Mumbai: 67-85.
  12. Shojaei AH, Chang RK, Guo X, Burnside BA, Couch RA (2001) Systemic drug delivery via the buccalmucosal route. Pharmaceutical Technology 70-81.
  13. Shah V, Patel SS, Jatav RK, Jain A, Sheorey RV (2008) Formulation and evaluation of mouth dissolving tablets of metoclopramide hydrochloride by direct compression technique Int J Drug Disc Herbal Res 1: 292-300.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 13249
  • [From(publication date):
    October-2015 - Oct 23, 2017]
  • Breakdown by view type
  • HTML page views : 9466
  • PDF downloads :3783
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords